Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225105 · ClinicalTrials.gov registry record · Phase 1
M3541 in Combination With Radiotherapy in Solid Tumors
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03225105 is a Phase 1 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 15 participants.
The verdict
NCT03225105, a Phase 1 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This dose-escalation study evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in participants with solid tumors with malignant lesions in the thorax, abdominal cavity, head and neck region, or extremities likely to benefit from palliative RT.
Interventions
- DRUG M3541
- RADIATION Palliative Radiotherapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225105
The ClinicalTrials.gov registry entry for NCT03225105 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which M3541 is the first listed.
NCT03225105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03225105 about?
NCT03225105 is a clinical study titled "M3541 in Combination With Radiotherapy in Solid Tumors". This dose-escalation study evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in participants with solid tumors with malignant lesions in the thorax, abdominal cavity, head a...
What is the current status of trial NCT03225105?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-09-06. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT03225105?
The interventions under investigation include: M3541 (DRUG), Palliative Radiotherapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT03225105?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.